|Bid||74.06 x 100|
|Ask||92.00 x 200|
|Day's Range||80.90 - 83.30|
|52 Week Range||75.81 - 100.51|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Uniqure NV (NASDAQ: QURE ) struck all-time highs last week and continued to linger near its peak value. One analyst projects 61-percent upside and considers the equity a top pick in 2018. The Rating Chardan ...
BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales. On the call, management is likely to comment on the launch preparation for pegvaliase.
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) is almost flat for the week after adding about 5 percent in the week ended April 13. Will the following catalytic events lead to a resumption ...
Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.
Spark Therapeutics (ONCE) is a leader in the field of gene therapy. Spark Therapeutics’ pipeline of gene therapy product candidates targets the retina, liver, and the central nervous system. Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations, and ten have given it “buy” recommendations.
CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with liver disease and other chronic diseases. Of the eight analysts covering CymaBay Therapeutics in April 2018, two analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating. Of the total 22 analysts covering Pfizer (PFE) in April 2018, two analysts have given the stock a “strong buy” rating, and nine analysts have given it a “buy” rating.
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their pipelines.
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
Increase in profitability and industry-beating performance can be essential considerations in a stock for some investors. In this article, I will take a look at BioMarin Pharmaceutical Inc’s (NASDAQ:BMRN) trackRead More...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
On April 9, 2018, Novartis AG (NVS) announced that it had entered into an agreement to acquire AveXis (AVXS), a clinical-stage gene therapy company, for ~$8.7 billion.
Take a look at Morningstar analysts' nine 'exponential technology' themes and some undervalued stocks poised to benefit from them.
Audentes, Spark and uniQure popped Tuesday after Novartis' $8.7 billion plan to buy AveXis put a spotlight on other gene therapy players.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding BMRN is favorable, with net inflows of $7.66 billion.
Roche offered additional details Thursday on the deaths of five patients taking its potential blockbuster drug Hemlibra.
BioMarin's (BMRN) MAA submission for its pipeline PKU candidate, pegvaliase, gets accepted in the EU. The same is under priority review in the United States with decision awaited this May.